Trial Profile
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Inbakicept (Primary) ; Necitumumab (Primary) ; Omega-3-acid ethyl esters (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUILT-3.090
- Sponsors ImmunityBio; NantKwest
- 10 Aug 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2021.
- 10 Aug 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2021.
- 14 Jul 2019 Planned primary completion date changed from 1 May 2019 to 1 Dec 2019.